Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30887869 | 1.00 | CYP3A4 (0.47) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL20604265 | 1.00 | CYP3A4 (0.47) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL31143650 | 0.87 | CYP3A4 (0.48) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL31143607 | 0.87 | CYP3A4 (0.48) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7759775 | 0.87 | CYP3A4 (0.48) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL23610049 | 0.87 | CYP3A4 (0.48) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL9777431 | 0.86 | SLC6A2 (0.54) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL4969094 | 0.83 | KDM4E (0.50) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5227874 | 0.83 | KDM4E (0.50) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL24925875 | 0.83 | CYP1A2 (0.47) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423433-B1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-12-17 | — | — | EP | disclosed |
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2019-07-16 | — | — | US | disclosed |
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2019-07-16 | — | — | US | disclosed |
| EP-3423433-A1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | Bio-Pharm Solutions Co., Ltd. (KR) | 2019-01-09 | — | — | EP | disclosed |
| EP-0948511-B1 | CHEMICAL SYNTHESIS OF NUCLEOSIDES ANALOGS AND THEIR INCORPORATION INTO POLYNUCLEOTIDES | SIRNA THERAPEUTICS INC (US) | 2006-10-18 | — | — | EP | disclosed |
| US-6248878-B1 | INCLUDING BASES 2-FLUOROPYRIDINE-3-YL, PYRIDINE-2-ONE-3-YL, PYRIDIN-2-(4-NITROPHENYLETHYL)-ONE-3-YL, 2-BROMOPYRIDINE-5-YL , PYRIDIN-2-ONE-5-YL, 2-AMINOPYRIDINE-5-YL, PYRIDIN-2-(4-NITROPHENYLETHYL)-ONE-5-YL; ANTISENSE/ANTICANCER AGENTS | RIBOZYME PHARMACEUTICALS, INC. | 2001-06-19 | — | — | US | disclosed |
| EP-0948511-A2 | CHEMICAL SYNTHESIS OF NUCLEOSIDES ANALOGS AND THEIR INCORPORATION INTO POLYNUCLEOTIDES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998028317-A2 | SYNTHESIS OF NUCLEOSIDES AND POLYNUCLEOTIDES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | STS, SULT2A1, SULT1A1 | CYP3A4 1003/4885CYP1A2 911/4885SLC6A3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.